{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nurix Therapeutics, Inc.
Who are in the management team of Nurix Therapeutics, Inc.?
As of March 2022, the management team of Nurix Therapeutics, Inc. includes Dr. David Lacey (Independent Non-Executive Chairman), Dr. Arthur Sands (President and CEO), and several Independent Directors: Dr. Leon Chen, Ms. Julia Gregory, Dr. Lori Kunkel, and Dr. Jeffrey Tong. They oversee the company's strategic direction and operations.
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapies to modulate protein levels for cancer and immune disorders. As of February 2025, it has a market cap of $868.32 million, with net sales of $18 million and a net loss of $56 million.
How big is Nurix Therapeutics, Inc.?
As of Jun 18, Nurix Therapeutics, Inc. has a market capitalization of 868.32 million, with net sales of 56.41 million and a net profit of -208.41 million over the last four quarters. The company reported shareholder's funds of 526.99 million and total assets of 675.43 million as of Nov 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
